May 19, 2021—Medical software company Medbaye announced the availability of its Clirra application after it received clearance under the FDA’s guidelines for device software functions and mobile medical applications.
The application draws from its database of peer-reviewed research and applies advanced Bayesian analysis to a clinician’s initial suspicion of disease presence and available diagnostic test results to provide a clear probability that a patient has a particular disease. Clirra also enables clinicians to perform what-if simulations of diagnostic tests, providing insight about how positive or negative test results may impact disease presence probability before ordering a test.
“Clirra represents a significant improvement in how physicians perform a differential diagnosis,” Eric Gluck, co-founder and CMO of Medbaye, said in a press release. “Studies show that the testing and assessment phase of the diagnostic pathway can present challenges to even the most experienced physician. Much of this is due to the difficulty of dealing with false-positive and false-negative laboratory and imaging results. This can lead to a delayed or inaccurate initial diagnosis. Our Clirra application addresses this issue, delivering the information needed to make clinical decisions with greater confidence.”
Clirra can be deployed as a mobile and desktop solution or embedded within other clinical data management and decision support tools.